File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Application of UPLC‐MS/MS to simultaneously detect four bioactive compounds in the tumour‐shrinking decoction (FM1523) for uterine fibroids treatment

TitleApplication of UPLC‐MS/MS to simultaneously detect four bioactive compounds in the tumour‐shrinking decoction (FM1523) for uterine fibroids treatment
Authors
Keywordsbioactive compounds
extraction
multiple reaction monitoring
tumor‐shrinking decoction
ultra‐pressure liquid chromatography coupled tandem mass spectrometry
Issue Date2019
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/5152
Citation
Phytochemical Analysis, 2019, v. 30 n. 4, p. 447-455 How to Cite?
AbstractIntroduction: The Chinese medicine formulation, tumour‐shrinking decoction (TSD, FM1523), which consists of 15 natural medicines, is used for uterine fibroids (UFs) therapy and possesses excellent clinical therapeutic effect. Objective: To develop a sensitive and validated analytical method for the simultaneous quantification of four crucial bioactive compounds including isorhamnetin‐3‐O‐neohesperidoside, curcumin, peimine and tetrahydropalmatine in the principal formulation of this decoction. Methods: An ultra‐performance liquid chromatography coupled tandem mass spectrometry (UPLC‐MS/MS) with an electrospray ionisation (ESI) source in multiple reaction monitoring (MRM) mode was conducted to investigate these bioactive compounds in the TSD. The chromatographic separation was performed on a C18 column when the flow rate was adjusted at 0.2 mL/min with gradient elution of acetonitrile–water with 0.1% formic acid. Accelerated solvent extraction (ASE) method with higher extraction efficiency was employed for TSD sample pre‐treatment. Results: The linearity, limit of detection (LOD) and limit of quantification (LOQ) were determined for this analytical method. The mean recoveries of the compounds were determined between 100.23% and 104.02% with satisfactory relative standard deviation (RSD) in the ranges of 2.65% to 3.81%. The precision was evaluated by intra‐day and inter‐day tests, which revealed RSD within the ranges of 1.21% to 2.14% and 1.24% to 2.32%, respectively. Conclusion: The bioactive compounds of TSD samples were successfully quantified via UPLC‐MS/MS with MRM mode. This study could help to evaluate the pharmacokinetic study of TSD during clinical applications and present a facile strategy for quantifying bioactive compounds in traditional Chinese Medicine decoction.
Persistent Identifierhttp://hdl.handle.net/10722/271260
ISSN
2021 Impact Factor: 3.024
2020 SCImago Journal Rankings: 0.574
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheng, ICC-
dc.contributor.authorLI, RK-
dc.contributor.authorLeung, GPH-
dc.contributor.authorLi, SL-
dc.contributor.authorKong, M-
dc.contributor.authorLao, LX-
dc.contributor.authorZhang, ZJ-
dc.contributor.authorLin, WL-
dc.contributor.authorNg, EHY-
dc.contributor.authorRong, JH-
dc.contributor.authorChen, JP-
dc.contributor.authorSu, J-
dc.contributor.authorZhang, KYB-
dc.contributor.authorMeng, W-
dc.date.accessioned2019-06-24T01:06:27Z-
dc.date.available2019-06-24T01:06:27Z-
dc.date.issued2019-
dc.identifier.citationPhytochemical Analysis, 2019, v. 30 n. 4, p. 447-455-
dc.identifier.issn0958-0344-
dc.identifier.urihttp://hdl.handle.net/10722/271260-
dc.description.abstractIntroduction: The Chinese medicine formulation, tumour‐shrinking decoction (TSD, FM1523), which consists of 15 natural medicines, is used for uterine fibroids (UFs) therapy and possesses excellent clinical therapeutic effect. Objective: To develop a sensitive and validated analytical method for the simultaneous quantification of four crucial bioactive compounds including isorhamnetin‐3‐O‐neohesperidoside, curcumin, peimine and tetrahydropalmatine in the principal formulation of this decoction. Methods: An ultra‐performance liquid chromatography coupled tandem mass spectrometry (UPLC‐MS/MS) with an electrospray ionisation (ESI) source in multiple reaction monitoring (MRM) mode was conducted to investigate these bioactive compounds in the TSD. The chromatographic separation was performed on a C18 column when the flow rate was adjusted at 0.2 mL/min with gradient elution of acetonitrile–water with 0.1% formic acid. Accelerated solvent extraction (ASE) method with higher extraction efficiency was employed for TSD sample pre‐treatment. Results: The linearity, limit of detection (LOD) and limit of quantification (LOQ) were determined for this analytical method. The mean recoveries of the compounds were determined between 100.23% and 104.02% with satisfactory relative standard deviation (RSD) in the ranges of 2.65% to 3.81%. The precision was evaluated by intra‐day and inter‐day tests, which revealed RSD within the ranges of 1.21% to 2.14% and 1.24% to 2.32%, respectively. Conclusion: The bioactive compounds of TSD samples were successfully quantified via UPLC‐MS/MS with MRM mode. This study could help to evaluate the pharmacokinetic study of TSD during clinical applications and present a facile strategy for quantifying bioactive compounds in traditional Chinese Medicine decoction.-
dc.languageeng-
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/5152-
dc.relation.ispartofPhytochemical Analysis-
dc.rightsThis is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectbioactive compounds-
dc.subjectextraction-
dc.subjectmultiple reaction monitoring-
dc.subjecttumor‐shrinking decoction-
dc.subjectultra‐pressure liquid chromatography coupled tandem mass spectrometry-
dc.titleApplication of UPLC‐MS/MS to simultaneously detect four bioactive compounds in the tumour‐shrinking decoction (FM1523) for uterine fibroids treatment-
dc.typeArticle-
dc.identifier.emailLeung, GPH: gphleung@hkucc.hku.hk-
dc.identifier.emailLao, LX: lxlao1@hku.hk-
dc.identifier.emailZhang, ZJ: zhangzj@hkucc.hku.hk-
dc.identifier.emailNg, EHY: nghye@hku.hk-
dc.identifier.emailRong, JH: jrong@hku.hk-
dc.identifier.emailChen, JP: abchen@hkucc.hku.hk-
dc.identifier.emailSu, J: sujing59@hku.hk-
dc.identifier.emailZhang, KYB: ybzhang@hku.hk-
dc.identifier.emailMeng, W: bmeng@hku.hk-
dc.identifier.authorityLeung, GPH=rp00234-
dc.identifier.authorityLao, LX=rp01784-
dc.identifier.authorityZhang, ZJ=rp01297-
dc.identifier.authorityNg, EHY=rp00426-
dc.identifier.authorityRong, JH=rp00515-
dc.identifier.authorityChen, JP=rp01316-
dc.identifier.authorityZhang, KYB=rp01410-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/pca.2827-
dc.identifier.pmid30916852-
dc.identifier.scopuseid_2-s2.0-85063549539-
dc.identifier.hkuros297958-
dc.identifier.volume30-
dc.identifier.issue4-
dc.identifier.spage447-
dc.identifier.epage455-
dc.identifier.isiWOS:000469994300008-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl0958-0344-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats